One To Watch
ProBioGen
Company Overview
A Berlin-based contract development and manufacturing organization specializing in biopharmaceuticals, viral vaccines, and biosimilars, with proprietary cell line and glycoengineering platforms licensed to global pharma and biotech partners. ProBioGen operates as a fully integrated CDMO, offering cell line development, process development, GMP manufacturing, and analytical services for proteins, antibodies, and viral vectors. The company's technology assets — including its AGE1.CR.pIX suspension cell line and GlymaxX glycoengineering platform — have been licensed to a broad roster of global pharmaceutical and biotech companies. Majority-owned by Egyptian drugmaker Minapharm Pharmaceuticals, ProBioGen sits at the intersection of CDMO services and proprietary technology licensing.
Headquarters and Global Presence
ProBioGen is headquartered in Berlin, Germany, with roots in the Charité university hospital ecosystem. Through its subsidiary MiGenTra GmbH, incorporated jointly with Minapharm, the company has established a Berlin headquarters and a principal manufacturing site in Cairo, Egypt, extending its production footprint into the Middle East and Africa region.
Founding and History
ProBioGen was founded in 1994 as a spin-off from the Charité, one of Europe's largest university hospitals, establishing early expertise in mammalian cell line engineering. The company built a reputation as a preferred CDMO partner for biopharmaceutical developers over the following two decades. A pivotal ownership change came when Egyptian drugmaker Minapharm Pharmaceuticals acquired 95% of ProBioGen's share capital for approximately 30.4 million euros (around $36.8 million), including milestone-linked earn-out payments. The MiGenTra GmbH subsidiary was incorporated in 2024 as a direct outcome of the Minapharm partnership, creating an integrated German-Egyptian manufacturing entity.
Therapy Areas and Focus
ProBioGen's CDMO and licensing activities span infectious diseases — particularly viral vaccines — and oncology, where its cell lines support therapeutic antibody and cancer vaccine manufacturing. The company's AGE1.CR.pIX cell line has been deployed in COVID-19 vaccine manufacturing programs, reflecting its relevance to pandemic preparedness and infectious disease response. On the oncology side, partnerships with Transgene for cancer vaccines and Spica Therapeutics for macrophage-targeted immunotherapies illustrate the breadth of ProBioGen's therapeutic client base. Biosimilar development, including a biosimilar trastuzumab program for Indonesia with Bio Farma, further diversifies its therapeutic footprint.
Technology Platforms and Modalities
ProBioGen's core proprietary technologies comprise three principal assets. The AGE1.CR.pIX suspension cell line is a chemically defined, serum-free avian cell platform optimized for viral vector and vaccine production, offering regulatory-friendly characteristics and scalability. The GlymaxX glycoengineering platform enables the production of afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity, relevant to oncology and immunology therapeutics — a technology Bayer has licensed for its own programs. The DirectedLuck Transposase System provides stable, high-yield integration of transgenes into mammalian cell lines, and has been licensed to Heat Biologics for biopharmaceutical manufacturing applications.
Key Pipeline and Programs
ProBioGen does not maintain its own clinical pipeline but enables client programs across multiple stages through technology licensing and CDMO services. The AGE1.CR.pIX cell line is the company's most widely deployed platform asset: City of Hope licensed it for a COVID-19 vaccine candidate, and Transgene holds a license for use in its personalized cancer vaccine manufacturing. The GlymaxX afucosylation platform has reached commercial licensing with Bayer, supporting antibody programs where enhanced effector function is therapeutically critical. On the biosimilar front, a trastuzumab biosimilar development agreement with Indonesia's state-owned Bio Farma targets one of the world's largest emerging pharmaceutical markets. Most recently, an MSA with Zag Bio covers cell line and process development for thymus-targeted central immune tolerance therapies, and the Spica Therapeutics collaboration focuses on monoclonal antibody development for pathogenic macrophage subset-targeted immunotherapy.
Recent Developments
Alfred Merz was formally appointed chief executive in April 2025, having joined the company from Bayer in 2024 and served as COO and interim CEO. In April 2026, Dr Simon Johannes Bulling joined as chief operating officer, strengthening the leadership team with operational depth. A master service agreement with Zag Bio was signed in January 2026, adding a central immune tolerance program to ProBioGen's client roster. The Spica Therapeutics collaboration on macrophage-targeted monoclonal antibody development was announced in December 2025.
Key Personnel
Alfred Merz serves as Chief Executive Officer. He brings more than 30 years of pharmaceutical industry experience, including senior roles at Bayer — where he was SVP and head of product supply for medical devices — and Novartis. Dr Simon Johannes Bulling serves as Chief Operating Officer, having joined in April 2026 to lead manufacturing and operational functions across ProBioGen's Berlin and MiGenTra sites.
Strategic Partnerships
ProBioGen's partnership portfolio spans major pharma and emerging biotech. Bayer has signed a commercial license for the GlymaxX technology, while Merck and Co and Millennium Pharmaceuticals have both engaged the company on cell line development programs. Client collaborations with Zymeworks, Chiome Bioscience, Heat Biologics, Transgene, Spica Therapeutics, and Zag Bio illustrate the breadth of its licensing and CDMO reach across North America, Europe, and Asia. The Bio Farma biosimilar trastuzumab agreement extends ProBioGen's commercial presence into Southeast Asia.
FAQ Section
Minapharm Pharmaceuticals of Egypt owns approximately 96.79% of ProBioGen following its circa $36.8 million acquisition. The relationship directly enabled the creation of MiGenTra GmbH, a Berlin-headquartered subsidiary with a Cairo manufacturing plant that gives the ProBioGen-Minapharm group an integrated European-African CDMO footprint. This positions the company to serve both established Western pharma markets and rapidly growing Middle Eastern and African biosimilar and vaccine markets.
AGE1.CR.pIX is a suspension-adapted, serum-free avian cell line derived from duck embryo origin, offering a chemically defined alternative to legacy egg-based or Vero cell manufacturing systems. Its freedom-to-operate profile, scalability in bioreactor formats, and suitability for a wide range of viral vectors make it attractive to vaccine developers seeking modern, regulatorily robust manufacturing platforms. City of Hope's adoption for COVID-19 vaccine manufacturing and Transgene's licensing for cancer vaccines demonstrate its versatility across infectious disease and oncology applications.
GlymaxX enables the production of afucosylated monoclonal antibodies — antibodies lacking the core fucose sugar on their Fc region — which can increase antibody-dependent cellular cytotoxicity by up to 100-fold compared to standard antibodies. This enhancement is achieved at the manufacturing cell line level rather than through post-production chemical modification, offering a cleaner regulatory and quality profile. Bayer's commercial license for GlymaxX validates its utility in next-generation therapeutic antibody programs targeting immuno-oncology and inflammatory disease.
DirectedLuck is ProBioGen's proprietary transposase-based gene integration system, designed to achieve stable, site-specific insertion of transgenes into mammalian host cell genomes. Compared to random integration approaches, directed systems reduce positional effects and can deliver more consistent, high-yield expression of therapeutic proteins. Heat Biologics licensed both DirectedLuck and ProBioGen's HEK293 suspension cell line under a research license agreement, reflecting demand for reliable, high-titer cell line development tools in biopharmaceutical manufacturing.
Infectious disease and oncology form the two dominant pillars. On the infectious disease side, COVID-19 vaccine programs and broader viral vector manufacturing underpin the AGE1.CR.pIX licensing business. Oncology is represented through cancer vaccine partnerships — notably with Transgene — as well as macrophage-targeted immunotherapy collaboration with Spica Therapeutics. Autoimmune and tolerance biology is an emerging frontier through the Zag Bio partnership, which is developing thymus-targeted therapies to induce central immune tolerance.
ProBioGen is an established, commercially active CDMO and technology licensor rather than a clinical-stage drug developer, meaning its milestones are contract wins, licensing deals, and manufacturing program expansions rather than clinical trial readouts. The company offers end-to-end services from cell line generation through GMP manufacturing, positioning it to serve clients from early discovery through commercial supply. The MiGenTra manufacturing expansion into Cairo signals a scaling phase as the Minapharm group seeks to build regional production capacity for biosimilars and vaccines.
Key watchpoints for ProBioGen include:
- Expansion of GlymaxX commercial licenses beyond Bayer, which would validate the platform's revenue potential at scale.
- Progress of MiGenTra's Cairo manufacturing facility toward GMP certification and commercial readiness.
- Growth of the Zag Bio and Spica Therapeutics programs into later clinical stages, which would increase manufacturing revenue and demonstrate client pipeline success.
- Execution risk associated with integrating Berlin CDMO operations with Minapharm's broader Egyptian pharmaceutical business.
- Competitive pressure from larger CDMOs such as Lonza, Samsung Biologics, and WuXi Biologics, which have significantly greater manufacturing scale and capital.
Latest ProBioGen News
Today's issue
| Headless Content Management with Blaze